Deals and Data

Deals and Data

UCSD study shows ocean bacteria make chemicals nearly identical to toxic man-made flame retardants. (U-T San Diego, 06/29/14)

GlaxoSmithKline and Theravance seek approval for their COPD inhaler Breo Ellipta for patients with asthma. (PharmaTimes Online, 06/30/14)

European Medicines Agency to review marketing authorization application of Merck’s investigational anti-PD-1 antibody pembrolizumab for the treatment of advanced melanoma. (PharmaTimes Online, 07/01/14)

CureVac licenses rights to Sanofi Pasteur to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. (GEN News, 07/01/14)

FDA to review Vertex Pharmaceuticals’ application for Kalydeco as treatment for cystic fibrosis patients 18 years or older with R117H mutation in the CFTR gene. (GenomeWeb, 07/02/14)

Study by UCSD and the Salk Institute shows artificial embryonic stem cells have quality problems. (U-T San Diego, 07/02/14)

SDSU and Scripps Institution of Oceanography study shows inhabited coral islands that engage in commercial fishing dramatically alter their nearby reef ecosystems. (San Diego State University, 07/03/14)

EU authorizes GlaxoSmithKline’s trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation. (Healio, 07/07/14)

Eli Lilly collaborates with Yabao Pharmaceutical Co to develop and sell one of their early-stage diabetes drugs, a glucokinase activator codenamed LY2608204, in China. (PharmaTimes Online,07/07/14)

Sanford-Burnham Medical Research Institute study shows brain cell survival and growth are controlled by a chemical switch activated by nitric oxide. (U-T San Diego, 07/07/14)

Microbiologics licenses Biomatrica's technology for use in its molecular controls for rapid diagnostic instruments and assays. (GenomeWeb, 07/08/14)

Boehringer Ingelheim’s experimental blood cancer drug meets main goal in a mid-stage trial and improved overall survival rate among patients. (Reuters, 07/08/14)

Sanofi and Regeneron Pharmaceuticals Inc. plan to test experimental eczema treatment in large late-stage studies after a smaller trial reduced symptoms of the scaly, itching disease. (Bloomberg, 07/09/14)

Bayer links up with the University of Oxford to develop gynecological therapies, focusing on endometriosis and uterine fibroids. (PharmaTimes Online, 07/09/14)

FDA accepts Sanofi's new drug application for an upgraded formulation of its insulin glargine (Lantus). (MedPage Today, 07/09/14)

Histogen establishes a joint venture for cancer therapy in partnership with the medical device company Wylde LLC. (U-T San Diego, 07/10/14)

Genomics England selects Illumina as preferred partner in the 100,000 Genomes Project; strives to gain better insight into cancer and other diseases to better treat them. (GenomeWeb, 07/11/14)

Otonomy files IPO after releasing positive Phase 3 data for its ear drug AuriPro, intended to reduce complications after children’s ear tube placement surgery. (U-T San Diego, 07/13/14)

San Diego is home to 48 of the world’s most influential scientists and engineers, including many Biocom members: UCSD, The Scripps Research Institute, Salk Institute for Biological Studies, SDSU, La Jolla Institute for Allergy and Immunology, J. Craig Venter Institute, Sanford-Burnham Medical Research Institute. (U-T San Diego, 07/13/14)

Former Biocom board chair and one of San Diego’s most enduring biotech stalwarts, Tina Nova, joins Illumina as senior vice president and general manager of its oncology business. (U-T San Diego, 07/14/14)

NIH awards TSRI scientists $2.6 million to produce specialized stem cells and help predict the behavior of human cells through animal models. (GEN News, 07/14/14)

Illumina will enlarge manufacturing options to make supplies for array of DNA sequencing devices. (U-T San Diego, 07/15/14)

Novartis and Google collaborate to develop “smart” contact lenses that would help diabetics track their blood glucose levels or restore the eye’s ability to focus. (The Globe and Mail, 07/15/14)

GSK and Codexis to use CodeEvolver protein engineering platform technology to develop new therapeutic, diagnostic, and prophylactic products in the human health field. (GEN News, 07/15/14)

Lightning strikes twice: Seragon Pharmaceuticals announces acquisition by Genentech one year after its predecessor company, Aragon Pharmaceuticals, was acquired. (Xconomy, 07/16/14)

Salk Institute researchers demonstrate a new way to restore insulin sensitivity in diabetic model mice. (U-T San Diego, 07/16/14)

« Return to Table of Contents